Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
CAR-PRISM
CAR- PRISM (PRecision Intervention Smoldering Myeloma)
- NCT05767359 ↗
- Active, not recruiting
- Dana-Farber Cancer Institute
- Deep
We haven't built an HCP commentary report on CAR-PRISM (ciltacabtagene autoleucel in high-risk smoldering multiple myeloma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on CAR-PRISM so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 25 | |
| YouTube | 16 | |
| Podcasts | 2 |
The trial
ClinicalTrials.gov- Official title
- CAR- PRISM (PRecision Intervention Smoldering Myeloma): A Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against BCMA in High-Risk Smoldering Myeloma
- Phase
- Phase 2
- Status
- Active, not recruiting
- Conditions
- Multiple Myeloma; Smoldering Multiple Myeloma
- Interventions
- Ciltacabtagene Autoleucel; Cyclophosphamide; Fludarabine Phosphate
- Arms
- Safety Run-In · Experimental
- Cilta-Cel Dose Expansion Cohort · Experimental
- Enrollment
- 20
- Primary outcomes
- Incidence of Dose Limiting Toxicities (DLT)
- Nature of Dose Limiting Toxicities (DLT)
- Incidence of Adverse Events (AEs)
- Sponsor
- Dana-Farber Cancer Institute with Janssen Research & Development, LLC
- Start
- Apr 19, 2023
- Primary completion
- Dec 15, 2025
- Results posted
- No
- Registry record
- NCT05767359 · updated Mar 12, 2026
Publications
linked from the registry- Nadeem O, Cordas Dos Santos DM, Nikiforow S, Bosch-Vilaseca A, O'Donnell E, Redd R, DeBraganca KC, Sperling AS, Liu Y, McEntire C, Arters F, O'Donnell C, Kineavy B, Marto M, Bergeron A, Swenson E, McHugh K, Caron A, Berry Q, Wei H, Durlacher E, Grimm E, Corrado F, Bidikian N, Montes de Oca R, Lengil T, De Wiest D, Gervais C, Panaro K, Smith EL, Anderson K, Jacobson C, Munshi NC, Richardson P, Madduri D, Schecter JM, Tendler C, Wildgust MA, Trippa L, Mateos MV, Ritz J, Ghobrial IM. Ciltacabtagene autoleucel in high-risk smoldering multiple myeloma: the CAR-PRISM phase 2 trial. Nat Med. 2026 Jul;32(7):2420-2429. doi: 10.1038/s41591-026-04365-y. Epub 2026 Apr 20. PubMed 42010117